Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02416622 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
A Phase 1 study of X-linked Retinoschisis, sponsored by Beacon Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 9
- Study locations
NCT02416622: Completed Phase 1 study of X-linked Retinoschisis, sponsored by Beacon Therapeutics.
NCT02416622 is a Phase 1 study of X-linked Retinoschisis that has completed, run by Beacon Therapeutics. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02416622, a Phase 1 study of X-linked Retinoschisis, has completed, sponsored by Beacon Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.
Primary Outcome
Number of participants with ocular adverse events, assessed by standard ophthalmic examination, including slit lamp biomicroscopy, tonometry, and indirect ophthalmoscopy.
Conditions Studied
Interventions
- BIOLOGICAL rAAV2tYF-CB-hRS1
Study Locations (9)
Texas
- Retina Foundation of the Southwest - Dallas
- Baylor College of Medicine, Alkek Eye Center - Houston
California
- University of California San Francisco, Dept. of Ophthalmology - San Francisco
Florida
- University of Miami - Miller School of Medicine Bascom Palmer Eye Institute - Miami
Maryland
- The Wilmer Eye Institute, Johns Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Michigan
- University of Michigan Kellogg Eye Center - Ann Arbor
North Carolina
- Duke Eye Center, Duke University Medical Center - Durham
Oregon
- Casey Eye Institute, Oregon Health and Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-05 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 1 |
What the finished NCT02416622 record still lists
NCT02416622 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with X-linked Retinoschisis appearing as the primary indexed condition, and to 1 intervention - of which rAAV2tYF-CB-hRS1 is the first listed.
NCT02416622 lists 9 locations in 8 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT02416622 about?
NCT02416622 is a clinical study titled "Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)". This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.
What is the current status of trial NCT02416622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-05. Estimated completion is 2023-05-09.
What conditions does trial NCT02416622 study?
This clinical trial studies the following conditions: X-linked Retinoschisis.
What interventions are being tested in trial NCT02416622?
The interventions under investigation include: rAAV2tYF-CB-hRS1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02416622?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02416622 being conducted?
This trial has 9 study locations across California, Florida, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for X-linked Retinoschisis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02416622's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia